pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
648
stories
24d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
24d
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
fiercebiotech
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
25d
MapLight dives despite positive data for schizophrenia drug
biopharma dive
25d
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
biopharma dive
25d
UPDATE: FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy
biospace
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
25d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
25d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
25d
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
biospace
25d
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
25d
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott
fiercebiotech
25d
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
26d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
26d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
26d
FDA has recommitted to adcomms—but to what end?
biospace
26d
Recon: WHO releases first interim list of medical device authorities; AstraZeneca using AI to hedge late-stage risks
raps
26d
Researchers find similar drug development to reimbursement timelines for major markets
raps
26d
Asia-Pacific Roundup: TGA adopts 23 international scientific guidelines
raps
28d
Sanofi halts development of troubled immune drug in eczema
biopharma dive
28d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
28d
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
biospace
28d
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
endpoints
28d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
28d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
28d
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
endpoints
28d
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
fiercebiotech
28d
Opinion: The U.S. pharmaceutical supply chain problem is not about China
stat
28d
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
stat
28d
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
← prev
page 9 of 22
next →
